OBJECTIVE: To study the long term risk of invasive cancer of the cervix or vagina after treatment for cervical intraepithelial neoplasia grade 3. DESIGN: Prospective cohort study. SETTING: Swedish cancer registry. PARTICIPANTS: All women in Sweden with severe dysplasia or cervical carcinoma in situ (equivalent to cervical intraepithelial neoplasia grade 3) treated during 1958-2002 (n=132,493) contributing 2,315,724 woman years. MAIN OUTCOME MEASURES: Standardised incidence ratios with risk of cancer in the Swedish general female population as reference, and relative risks in multivariable log-linear regression model, with internal references. RESULTS: Women with previous cervical intraepithelial neoplasia grade 3 had an increased risk of invasive cervical cancer compared with the general female population (standardised incidence ratio 2.34, 95% confidence interval 2.18 to 2.50). The increased risk showed a decreasing trend with time since diagnosis for women treated later than 1970 but the risk was still increased after 25 years. An effect of age was found, with an accentuated increase in risk for women aged more than 50. The excess risk for cervical cancer associated with previous cervical intraepithelial neoplasia grade 3 has steadily increased since 1958. For vaginal cancer the standardised incidence ratio was 6.82 (5.61 to 8.21) but this decreased to 2.65 after 25 years. Adjustments in the multivariable log-linear regression model did not substantially alter these results. CONCLUSIONS: Women previously treated for cervical intraepithelial neoplasia grade 3 are at an increased risk of developing invasive cervical cancer and vaginal cancer. This risk has increased since the 1960s and is accentuated in women aged more than 50. The risk is still increased 25 years after treatment.
OBJECTIVE: To study the long term risk of invasive cancer of the cervix or vagina after treatment for cervical intraepithelial neoplasia grade 3. DESIGN: Prospective cohort study. SETTING: Swedish cancer registry. PARTICIPANTS: All women in Sweden with severe dysplasia or cervical carcinoma in situ (equivalent to cervical intraepithelial neoplasia grade 3) treated during 1958-2002 (n=132,493) contributing 2,315,724 woman years. MAIN OUTCOME MEASURES: Standardised incidence ratios with risk of cancer in the Swedish general female population as reference, and relative risks in multivariable log-linear regression model, with internal references. RESULTS:Women with previous cervical intraepithelial neoplasia grade 3 had an increased risk of invasive cervical cancer compared with the general female population (standardised incidence ratio 2.34, 95% confidence interval 2.18 to 2.50). The increased risk showed a decreasing trend with time since diagnosis for women treated later than 1970 but the risk was still increased after 25 years. An effect of age was found, with an accentuated increase in risk for women aged more than 50. The excess risk for cervical cancer associated with previous cervical intraepithelial neoplasia grade 3 has steadily increased since 1958. For vaginal cancer the standardised incidence ratio was 6.82 (5.61 to 8.21) but this decreased to 2.65 after 25 years. Adjustments in the multivariable log-linear regression model did not substantially alter these results. CONCLUSIONS:Women previously treated for cervical intraepithelial neoplasia grade 3 are at an increased risk of developing invasive cervical cancer and vaginal cancer. This risk has increased since the 1960s and is accentuated in women aged more than 50. The risk is still increased 25 years after treatment.
Authors: W P Soutter; A de Barros Lopes; A Fletcher; J M Monaghan; I D Duncan; E Paraskevaidis; H C Kitchener Journal: Lancet Date: 1997-04-05 Impact factor: 79.321
Authors: Janet R Daling; Margaret M Madeleine; Stephen M Schwartz; Katherine A Shera; Joseph J Carter; Barbara McKnight; Peggy L Porter; Denise A Galloway; James K McDougall; Hisham Tamimi Journal: Gynecol Oncol Date: 2002-02 Impact factor: 5.482
Authors: K Hellman; C Silfverswärd; B Nilsson; A C Hellström; B Frankendal; F Pettersson Journal: Int J Gynecol Cancer Date: 2004 May-Jun Impact factor: 3.437
Authors: Michelle J Khan; L Stewart Massad; Walter Kinney; Michael A Gold; E J Mayeaux; Teresa M Darragh; Philip E Castle; David Chelmow; Herschel W Lawson; Warner K Huh Journal: Gynecol Oncol Date: 2016-02-22 Impact factor: 5.482
Authors: Hans-Georg Schnürch; Sven Ackermann; Celine D Alt-Radtke; Lukas Angleitner; Jana Barinoff; Matthias W Beckmann; Carsten Böing; Christian Dannecker; Tanja Fehm; Rüdiger Gaase; Paul Gass; Marion Gebhardt; Friederike Gieseking; Andreas Günthert; Carolin C Hack; Peer Hantschmann; Lars Christian Horn; Martin C Koch; Anne Letsch; Peter Mallmann; Bernhard Mangold; Simone Marnitz; Grit Mehlhorn; Kerstin Paradies; Michael J Reinhardt; Reina Tholen; Uwe Torsten; Wolfgang Weikel; Linn Wölber; Monika Hampl Journal: Geburtshilfe Frauenheilkd Date: 2019-07-16 Impact factor: 2.915
Authors: Joy Melnikow; Colleen McGahan; George F Sawaya; Thomas Ehlen; Andrew Coldman Journal: J Natl Cancer Inst Date: 2009-05-12 Impact factor: 13.506
Authors: Rebecca B Perkins; Richard L Guido; Mona Saraiya; George F Sawaya; Nicolas Wentzensen; Mark Schiffman; Sarah Feldman Journal: J Womens Health (Larchmt) Date: 2021-01 Impact factor: 2.681
Authors: Matejka Rebolj; Theo Helmerhorst; Dik Habbema; Caspar Looman; Rob Boer; Joost van Rosmalen; Marjolein van Ballegooijen Journal: BMJ Date: 2012-10-31